Abstract is: Pralatrexate, sold under the brand name Folotyn, is a medication used for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Pralatrexate was approved for medical use in the United States in September 2009, as the first treatment for Peripheral T-cell Lymphoma (PTCL), an often aggressive type of non-Hodgkins lymphoma.
| P3780 | active ingredient in | Folotyn | Q29005877 |
| P366 | has use | medication | Q12140 |
| P8026 | LiverTox likelihood score | LiverTox toxicity likelihood category E* | Q83284878 |
| P2067 | mass | 477.176067 | |
| P2175 | medical condition treated | mature T-cell and NK-cell lymphoma | Q18553445 |
| P129 | physically interacts with | dihydrofolate reductase | Q417149 |
| P9989 | stylized name | PRALAtrexate | |
| P2868 | subject has role | protein synthesis inhibitor | Q7251505 |
| P2275 | World Health Organisation international non-proprietary name | pralatrexate |